Monitoring of the Sensitivity In Vivo of <i>Plasmodium falciparum</i> to Artemether-Lumefantrine in Mali
oleh: Modibo Diarra, Drissa Coulibaly, Amadou Tapily, Boureima Guindo, Koualy Sanogo, Diakalia Koné, Youssouf Koné, Karim Koné, Aboudramane Bathily, Oumar Yattara, Mahamadou A. Thera, Alassane Dicko, Abdoulaye A. Djimdé, Issaka Sagara
| Format: | Article |
|---|---|
| Diterbitkan: | MDPI AG 2021-01-01 |
Deskripsi
In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented. This work evaluated the treatment according to the World Health Organization’s standard 28-day treatment method. The primary endpoint was the clinical and parasitological response corrected by a polymerase chain reaction. It was more than 99.9 percent, the proportion of patients with anemia significantly decrease compared to baseline (<i>p</i> < 0.001), and no serious events were recorded. <i>Plasmodium falciparum</i> remains sensitive to artemether-lumefantrine in Mali.